Association of Performance on the Financial Capacity Instrument-Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
ppublish
Résumé
To investigate the association of the Financial Capacity Instrument-Short Form (FCI-SF) performance and timing total scores with brain β-amyloid and cortical thickness in cognitively unimpaired (CU) (at baseline) older adults. A total of 309 participants (aged 70 years or older) of the Mayo Clinic Study of Aging underwent Participants' mean age (SD) was 80.2 (4.8) years (56.3% male individuals). In cross-sectional analysis, abnormal amyloid PET (vs normal) was associated with a lower FCI-SF total score and slower total composite time. In longitudinal analysis, FCI-SF total score declined faster (difference in annualized rate of change, beta coefficient [β] [95% confidence interval (CI)] = -1.123 [-2.086 to -0.161]) and FCI-SF total composite time increased faster (difference in annualized rate of change, β [95% CI] = 16.274 [5.951 to 26.597]) for participants with neurodegeneration at baseline (vs those without). Participants who exhibited both abnormal amyloid PET and neurodegeneration at baseline had a greater increase in total composite time when compared with the group without abnormal amyloid and without neurodegeneration (difference in annualized rate of change, β [95% CI] = 16.750 [3.193 to 30.307]). Performance and processing speed on the FCI-SF were associated with imaging biomarkers of AD pathophysiology in CU (at baseline) older adults. Higher burdens of imaging biomarkers were associated with longitudinal worsening on FCI-SF performance. Additional research is needed to delineate further these associations and their predictive utility at the individual person level.
Sections du résumé
Background and Objectives
UNASSIGNED
To investigate the association of the Financial Capacity Instrument-Short Form (FCI-SF) performance and timing total scores with brain β-amyloid and cortical thickness in cognitively unimpaired (CU) (at baseline) older adults.
Methods
UNASSIGNED
A total of 309 participants (aged 70 years or older) of the Mayo Clinic Study of Aging underwent
Results
UNASSIGNED
Participants' mean age (SD) was 80.2 (4.8) years (56.3% male individuals). In cross-sectional analysis, abnormal amyloid PET (vs normal) was associated with a lower FCI-SF total score and slower total composite time. In longitudinal analysis, FCI-SF total score declined faster (difference in annualized rate of change, beta coefficient [β] [95% confidence interval (CI)] = -1.123 [-2.086 to -0.161]) and FCI-SF total composite time increased faster (difference in annualized rate of change, β [95% CI] = 16.274 [5.951 to 26.597]) for participants with neurodegeneration at baseline (vs those without). Participants who exhibited both abnormal amyloid PET and neurodegeneration at baseline had a greater increase in total composite time when compared with the group without abnormal amyloid and without neurodegeneration (difference in annualized rate of change, β [95% CI] = 16.750 [3.193 to 30.307]).
Discussion
UNASSIGNED
Performance and processing speed on the FCI-SF were associated with imaging biomarkers of AD pathophysiology in CU (at baseline) older adults. Higher burdens of imaging biomarkers were associated with longitudinal worsening on FCI-SF performance. Additional research is needed to delineate further these associations and their predictive utility at the individual person level.
Identifiants
pubmed: 35747890
doi: 10.1212/CPJ.0000000000001157
pii: NEURCLINPRACT2021069749
pmc: PMC9208409
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113-124Subventions
Organisme : NIA NIH HHS
ID : R01 AG041851
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS097495
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057708
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG021927
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Informations de copyright
© 2022 American Academy of Neurology.
Références
Neurology. 2009 Sep 22;73(12):928-34
pubmed: 19770468
J Prev Alzheimers Dis. 2019;6(4):274-282
pubmed: 31686100
Brain. 2018 May 1;141(5):1517-1528
pubmed: 29538647
Brain Imaging Behav. 2013 Sep;7(3):282-92
pubmed: 23504597
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
J Am Geriatr Soc. 2018 Oct;66(10):1940-1947
pubmed: 30207586
Nat Rev Drug Discov. 2007 Apr;6(4):295-303
pubmed: 17347655
Neuroimage. 2005 Jun;26(2):600-8
pubmed: 15907317
J Gerontol A Biol Sci Med Sci. 2016 Mar;71(3):391-7
pubmed: 26419979
Ann Clin Transl Neurol. 2020 Apr;7(4):474-485
pubmed: 32314554
J Am Geriatr Soc. 2010 Feb;58(2):265-74
pubmed: 20374402
Brain. 2009 May;132(Pt 5):1355-65
pubmed: 19339253
JAMA. 2019 Jun 18;321(23):2316-2325
pubmed: 31211344
Arch Clin Neuropsychol. 2019 Mar 01;34(2):152-161
pubmed: 29617705
Dement Geriatr Cogn Disord. 2011;31(6):443-50
pubmed: 21778725
Arch Neurol. 2000 Jun;57(6):877-84
pubmed: 10867786
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808
Psychol Assess. 2016 Jun;28(6):737-49
pubmed: 26168311
J Gerontol. 1982 May;37(3):323-9
pubmed: 7069156
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
J Alzheimers Dis. 2014;41(3):719-28
pubmed: 24685624
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Neurology. 2003 Feb 11;60(3):449-57
pubmed: 12578926
Neurology. 2010 Sep 7;75(10):889-97
pubmed: 20820000
Nature. 2009 Oct 15;461(7266):916-22
pubmed: 19829371
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Arch Neurol. 1991 Jul;48(7):725-8
pubmed: 1859300
Am J Geriatr Psychiatry. 2008 Mar;16(3):209-19
pubmed: 18263665
Neurology. 2012 May 15;78(20):1576-82
pubmed: 22551733
Neurobiol Aging. 2011 Jul;32(7):1207-18
pubmed: 19660834
J Am Geriatr Soc. 2018 Dec;66(12):2274-2281
pubmed: 30462843
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Am J Geriatr Psychiatry. 2013 Apr;21(4):382-90
pubmed: 23498385